02:48:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-03 Bokslutskommuniké 2024
2024-11-01 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-06-26 Årsstämma 2024
2024-04-26 Ordinarie utdelning BRAIN 0.00 SEK
2024-04-15 Kvartalsrapport 2024-Q1
2024-02-29 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-12 Ordinarie utdelning BRAIN 0.00 SEK
2023-05-11 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2023-02-15 Extra Bolagsstämma 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-12 Ordinarie utdelning BRAIN 0.00 SEK
2022-05-11 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-31 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning BRAIN 0.00 SEK
2021-04-15 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning BRAIN 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-30 Kvartalsrapport 2019-Q2
2019-06-17 Årsstämma 2019
2019-04-08 Ordinarie utdelning BRAIN 0.00 SEK
2019-02-28 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-07-25 Extra Bolagsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-04-19 Ordinarie utdelning BRAIN 0.00 SEK
2018-04-18 Årsstämma 2018
2018-02-16 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-10 Kvartalsrapport 2017-Q2
2017-06-29 Årsstämma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-04-24 Extra Bolagsstämma 2017
2017-04-12 Ordinarie utdelning BRAIN 0.00 SEK
2017-02-14 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-14 Årsstämma 2016
2016-03-27 Ordinarie utdelning BRAIN 0.00 SEK
2016-01-28 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-04-28 Kvartalsrapport 2015-Q1
2015-03-27 Ordinarie utdelning BRAIN 0.00 SEK
2015-03-26 Årsstämma 2015
2015-01-27 Bokslutskommuniké 2014
2014-10-20 Kvartalsrapport 2014-Q3
2014-08-19 Kvartalsrapport 2014-Q2
2014-06-26 Ordinarie utdelning BRAIN 0.00 SEK
2014-06-25 Årsstämma 2014
2014-04-14 Extra Bolagsstämma 2014

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
BrainCool är verksamt inom medicinteknik. Bolaget utvecklar produkter som används inom medicinsk kylning av hjärnan. Teknologin är utvecklad som kylkuddar som appliceras på olika delar av patientens kropp, där systemet kontrollerar kroppstemperaturen. Produkterna används vid behandling av olika allvarliga tillstånd innefattande stroke, hjärtstopp, samt hjärnskakning och migrän. BrainCool grundades 2010 och har sitt huvudkontor i Lund.
2023-05-29 16:16:00

The newly published guidelines by The Neuroprotective Therapy Consensus Review Group (NTCR) a group of leading researchers from the UK and Italy, (https://www.sciencedirect.com/science/article/pii/S0007091223002052) aim to improve the quality of targeted temperature management for patients with neurological fever after intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke in critical care.

These recommendations have been approved by the Neuro Anaesthesia and Critical Care Society (NACCS), UK and have been published in the British Journal of Anaesthesia.

CEO Martin Waleij comments:

“The new guideline recommendation, that is being implemented in the UK will serve yet another important tool for the development of TTM within ICU and pave the way to similar guidelines in Europe. 

In the US market, guidelines by the US Neurocritical Society was implemented already in 2017 (https://www.neurocriticalcare.org/Portals/0/Docs/Resources/TTM_Guideline.pdf)

The need for the use of high quality TTM system is highlighted in the new UK guidelines, which further will benefit BrainCool as well on the US market. The quick development of treatment of neurological fever serves as a solid foundation for strong growth in the TTM space the coming years.

There are approximately 7,000 acute and critical care hospitals in the United States, of which 2,000 hospitals have more than 100 ICU beds and more advanced care so there is a large potential to process. The average utilization rate, i.e, the number of treated patients per system, has increased significantly. “
 

Fever is commonly found in patients admitted to neurocritical care. It has been found to increase the risk of complications and is often associated with unfavourable clinical outcome. Specifically, fever occurs in up to 40% of patients with ischemic stroke[1] and intracerebral hemorrhage[2] and up to 70% of all patients with severe traumatic brain injury (TBI)[3] or subarachnoid hemorrhage (SAH)[4] within the first 10 days following injury.[5] Regardless of its cause, it is linked to higher mortality, poor neurological outcome, and prolonged length of stay in the intensive care unit (ICU) and hospital.[6, 7]

Accordingly, it is recommended that fever should be aggressively controlled by continuously monitoring the core temperature and targeted temperature management (TTM) commences within 1 h of the first fever with temperature maintained between 36.0°C and 37.5°C using automated feedback-controlled devices, with shivering managed to limit the risk of secondary injury. The group agreed that the maximum temperature variation that these patients should experience during TTM for normothermia is ideally less than plus or minus 0.5°C per hour, and <1°C per 24-h period. Practically, this translates as a recommendation to initiate TTM when core temperature exceeds 37.5°C, and to select a target temperature between 36.5°C and 37.0°C. Also, it recommends against the use of non-automated methods of temperature control.

References:

1. Azzimondi, G., et al., Fever in acute stroke worsens prognosis. A prospective study. Stroke, 1995. 26(11): p. 2040-3.
2. Schwarz, S., et al., Incidence and prognostic significance of fever following intracerebral hemorrhage. Neurology, 2000. 54(2): p. 354-61.
3. Rincon, F., et al., Brain injury as a risk factor for fever upon admission to the intensive care unit and association with in-hospital case fatality: a matched cohort study. J Intensive Care Med, 2015. 30(2): p. 107-14.
4. Fernandez, A., et al., Fever after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology, 2007. 68(13): p. 1013-9.
5. Oliveira-Filho, J., et al., Fever in subarachnoid hemorrhage: relationship to vasospasm and outcome. Neurology, 2001. 56(10): p. 1299-304.
6. Rincon, F., et al., The epidemiology of spontaneous fever and hypothermia on admission of brain injury patients to intensive care units: a multicenter cohort study. J Neurosurg, 2014. 121(4): p. 950-60.
7. Diringer, M. N., et al., Elevated body temperature independently contributes to increased length of stay in neurologic intensive care unit patients. Crit Care Med, 2004. 32(7): p. 1489-95.